Evonik, a Germany-based specialist chemicals company, has opened its largest medical device applications centre in Shanghai, aimed at supporting the growing demand for advanced medical technologies across Asia.
The new facility specialises in the research, development, and processing of semi-finished components for bioresorbable medical devices.
As Asia’s medical device market, particularly China’s, anticipates double-digit growth, driven by rising healthcare standards and supportive government policies like the Healthy China 2030 initiative, Evonik’s new centre is positioned to help customers innovate high-performance, next-generation medical devices.
The new facility specialises in the research, development, and processing of semi-finished components for bioresorbable medical devices
The Evonik Shanghai Medical Device Centre offers comprehensive, one-stop solutions covering concept development, material selection and customisation, prototyping and processing, analytical services, quality and regulatory documentation, and the manufacturing of semi-finished products and components in an ISO Class 7 cleanroom environment.
By utilising advanced processing technologies, the centre converts Evonik’s wide range of standard and bespoke biomaterials into various types of semi-finished components.
These are designed with specific properties, including bioresorbability, low friction, antithrombotic, and antibacterial characteristics.
Medical device manufacturers can then further process them to meet precise requirements for diverse applications in orthopaedics, sports medicine, general surgery, cardiovascular care, neurosurgery, urology, aesthetics, ophthalmology, and dental care.
The Evonik Shanghai Medical Device Centre offers comprehensive, one-stop solutions
It transforms Evonik’s proprietary and customisable biomaterials into semi-finished components with specialised properties like bioresorbability, low-friction, antithrombotic, and antibacterial characteristics for applications in orthopedics, cardiovascular care, surgery, ophthalmology, dental care, and more.
“This addition to our global technical service network will help more customers in Asia reduce complexity, accelerate time to market, and improve device performance,” said Yann d’Hervé, Head of Evonik Health Care.
Evonik’s expanding portfolio includes bioresorbable polymers, biosynthetic cellulose, surface modification technologies, and recombinant collagen, providing advanced, safe, and patient-specific solutions for high-end medical consumables
Top image: Evonik's new medical device centre in Shanghai
